GlassScriptPhysician profile
Justin M Goldfarb
NPI 1215152723
$26,466.40
in general payments reported to CMS, 2019-2025
47 companies · $3,118 in 2025
The $3,118 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $649 · 2021: $3,658 · 2022: $3,765 · 2023: $278 · 2024: $3,368 · 2025: $3,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,850 · Education: $495 · Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,850.00 |
| Education | $494.84 |
| Food and Beverage | $418.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,842.22 | 2019-2025 | Imfinzi |
| Abbvie INC. | $6,690.79 | 2019-2022 | |
| Beigene USA, INC. | $2,550.00 | 2024 | Tevimbra, Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,386.14 | 2019 | |
| Incyte Corporation | $1,214.98 | 2019-2025 | |
| Amgen INC. | $415.43 | 2019-2021 | |
| Janssen Biotech, INC. | $362.71 | 2019-2025 | Imbruvica, Tecvayli, Talvey |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $299.85 | 2023-2024 | |
| Dova Pharmaceuticals | $236.94 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $212.62 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $206.91 | 2019 | |
| Daiichi Sankyo INC. | $203.98 | 2019-2024 | Enhertu |
| Novocure Gmbh | $200.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.11 | 2019-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Goldfarb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.